Protalix BioTherapeutics (Protalix BioTherapeutics) Cash, Cash Equivalents, Marketable Securities : $44.56 Mil (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Protalix BioTherapeutics Cash, Cash Equivalents, Marketable Securities?

Protalix BioTherapeutics's quarterly cash, cash equivalents, marketable securities declined from Jun. 2023 ($48.18 Mil) to Sep. 2023 ($40.98 Mil) but then increased from Sep. 2023 ($40.98 Mil) to Dec. 2023 ($44.56 Mil).

Protalix BioTherapeutics's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($38.99 Mil) to Dec. 2022 ($22.18 Mil) but then increased from Dec. 2022 ($22.18 Mil) to Dec. 2023 ($44.56 Mil).

Protalix BioTherapeutics Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Protalix BioTherapeutics's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protalix BioTherapeutics Cash, Cash Equivalents, Marketable Securities Chart

Protalix BioTherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

17.79

38.55

38.99

22.18

44.56

Protalix BioTherapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															22.18	33.04	48.18	40.98	44.56

Protalix BioTherapeutics Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Protalix BioTherapeutics (AMEX:PLX) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Protalix BioTherapeutics Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Protalix BioTherapeutics's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Protalix BioTherapeutics (Protalix BioTherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protalix BioTherapeutics Inc (AMEX:PLX) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

PBDA:Germany

Address

2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601

Website

https://www.protalix.com

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement.

Executives

Dror Bashan	director, officer: President and CEO	2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 L3 20100
Eliot Forster	director	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Aharon Schwartz	director	C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100
Zvi Shmuel Ben	director	2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 2161401
Dexcel Pharma Technologies Ltd.	10 percent owner	1 DEXCEL STREET, OR AKIVA L3 3060000
Dan Oren	10 percent owner	1 DEXCEL STREET, OR AKIVA L3 30600000
Eyal Rubin	officer: Sr. VP and CFO	C/O BRAINSTORM CELL THERAPEUTICS INC.,, 3 UNIVERSITY PLAZA DRIVE, STE 320, HACKENSACK NJ 07601
Yaron Naos	officer: Sr. VP, Operations	2 SNUNIT STREET, SCIENCE PARK, POB 455, CARMIEL L3 20100
Yael Hayon	officer: Vice President, R&D	2 SNUNIT STREET, SCIENCE PARK, POB 455, CARMIEL L3 2161401
Zeev Bronfeld	director	6 URI STREET, TEL AVIV L3 64954
Amos Bar-shalev	director	C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 20100
David Granot	director	6225 NEIL ROAD, RENO NV 89511
Pol F Boudes	director	C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Gwen A Melincoff	director	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Moshe Manor	officer: President & CEO	C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100